These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 7361790)

  • 41. Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step.
    Castagne V; Habert H; Abbara C; Rudant E; Bonhomme-Faivre L
    J Oncol Pharm Pract; 2011 Sep; 17(3):191-6. PubMed ID: 20630921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sterility-testing program for antibiotics and other intravenous admixtures.
    Choy FN; Lamy PP; Burkhart VD; Tenney JH
    Am J Hosp Pharm; 1982 Mar; 39(3):452-6. PubMed ID: 7041640
    [No Abstract]   [Full Text] [Related]  

  • 43. Centralized intravenous admixture program for nine British hospitals.
    Tallett ER
    Am J Hosp Pharm; 1978 Feb; 35(2):163-5. PubMed ID: 626198
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Method for testing aseptic technique of intravenous admixture personnel.
    Dirks I; Smith FM; Furtado D; White SJ; Godwin HN
    Am J Hosp Pharm; 1982 Mar; 39(3):457-9. PubMed ID: 7041641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Formulation and stability study of sucred solutions for a clinical trial in neonates].
    Senis-Loiseau C; Vaillant C; Markiewicz-Massy A; Torck M; Thielmans B
    Ann Pharm Fr; 2003 Nov; 61(6):425-30. PubMed ID: 14639195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of intravenous infusion fluids manufactured in Kenya.
    Aluoch-Orwa JA; Ondari CO; Kibwage IO; Hoogmartens J
    East Afr Med J; 1995 Dec; 72(12):800-4. PubMed ID: 8689981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a device for monitoring sterility of injectable fluids.
    Mayhall CG; Pierpaoli PG; Hall GO; Thomas RB
    Am J Hosp Pharm; 1981 Aug; 38(8):1148-50. PubMed ID: 6791498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Premixed intravenous admixtures: a positive development for hospital pharmacy.
    Lee HE
    Am J Hosp Pharm; 1983 Jun; 40(6):1043-4. PubMed ID: 6869393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Methods for ensuring the apyrogenic quality of injection solutions in hospital pharmacies].
    Eroshevskiĭ AA; Khveshchuk PF; Riabykh LD
    Voen Med Zh; 1991 Mar; (3):59-60. PubMed ID: 1853599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality assurance: ensuring pharmacy personnel follow procedures for handling cytotoxic drugs.
    Scott BE; White SJ; Matthews T
    Hosp Pharm; 1987 Jan; 22(1):45-9. PubMed ID: 10280293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reducing waste of intravenous solutions.
    Diehl LD; Goo ED; Sumiye L; Ferrell R
    Am J Hosp Pharm; 1992 Jan; 49(1):106-8. PubMed ID: 1570849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nitroglycerin injection manufactured by a hospital pharmacy.
    Clarke AJ; Watkins RE
    Am J Hosp Pharm; 1985 Jul; 42(7):1542-6. PubMed ID: 3927720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Measurement and regulation of the quality of medicinal dosage forms. XII. Contribution on the method of determination of mechanical impurities in infusion solutions].
    Zácek H; Zatloukal Z
    Cesk Farm; 1977 Oct; 26(8):377-9. PubMed ID: 608198
    [No Abstract]   [Full Text] [Related]  

  • 54. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.
    Sunenshine RH; Tan ET; Terashita DM; Jensen BJ; Kacica MA; Sickbert-Bennett EE; Noble-Wang JA; Palmieri MJ; Bopp DJ; Jernigan DB; Kazakova S; Bresnitz EA; Tan CG; McDonald LC
    Clin Infect Dis; 2007 Sep; 45(5):527-33. PubMed ID: 17682984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outsourcing inpatient i.v. compounding: expense and medication error implications.
    Burruss RA; Carroll NV; Schraa C; Burton B
    Pharm Pract Manag Q; 1996 Oct; 16(3):52-9. PubMed ID: 10166235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyrogen contamination of total parenteral nutrition solutions: a case report.
    Stansfield SA; Jones EL
    Can J Hosp Pharm; 1983; 36(1):21, 28. PubMed ID: 10310172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hazards surround I.V. admixtures.
    Dinel B
    Hosp Adm Can; 1978 Sep; 20(9):21, 23. PubMed ID: 10239185
    [No Abstract]   [Full Text] [Related]  

  • 58. Comprehensive intravenous admixture services: logistics and quality assurance in a university affiliated teaching institution.
    Wellman GS; Hale KM; Schneider PJ; Hale KN
    Hosp Pharm; 1984 Sep; 19(9):601-6. PubMed ID: 10267935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bulk compounding in Canadian hospitals--a survey.
    Taddio A; Wilson W
    Can J Hosp Pharm; 1990 Oct; 43(5):213-8, xxxii. PubMed ID: 10107923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of an IV admixture program in a 167-bed hospital.
    Wyatt BK
    Hosp Pharm; 1975 Jun; 10(6):225-9. PubMed ID: 10237880
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.